This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xi, L. Articles by Godfrey, T. E. Search for Related Content PubMed PubMed Citation Articles by Xi, L. Articles by Godfrey, T. E.

Molecular Staging of Lymph Nodes from Patients with Esophageal Adenocarcinoma

Departments of ¹ Surgery and ² Biostatistics, University of Pittsburgh; The ³ University of Pittsburgh Cancer Institute; ⁴ Redpath Integrated Pathology, Pittsburgh, Pennsylvania; and ⁵ Mount Sinai School of Medicine, New York, New York

Requests for reprints: Tony E. Godfrey, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1668, New York, NY 10029. Phone: 212-659-9082; Fax: 212-849-2523; E-mail: tony.godfrey{at}mssm.edu.

Purpose: This study was designed to evaluate molecular markers for the detection of micrometastasis in esophageal adenocarcinoma, define algorithms to distinguish positive from benign lymph nodes and to validate these findings in an independent tissue set and in patients with p_N0 esophageal adenocarcinoma.

Experimental Design: Potential markers were identified through literature and database searches. All markers were analyzed by quantitative reverse transcription (QRT)-PCR on a limited set of primary tumors and benign lymph nodes. Selected markers were further evaluated on a larger tissue set and classification algorithms were generated for individual markers and combinations. Algorithms were statistically validated internally as well as externally on an independent set of lymph nodes. Selected markers were then used to identify occult disease in lymph nodes from 34 patients with p_N0 esophageal adenocarcinoma.

Results: Thirty-nine markers were evaluated, six underwent further analysis and five were analyzed in the external validation study. Two markers provided perfect classification in both the screening and validation sets, although parametric bootstrap analysis estimated 2% to 3% optimism in the observed classification accuracy. Several marker combinations also gave perfect classification in the observed data sets, and estimates of optimism were lower, implying more robust classification than with individual markers alone. Five of thirty-four patients with esophageal adenocarcinoma had positive nodes by multimarker QRT-PCR analysis and disease-free survival was significantly worse in these patients (P = 0.0023).

Conclusions: We have identified novel QRT-PCR markers for the detection of occult lymph node disease in patients with esophageal adenocarcinoma. The objective nature of QRT-PCR results, and the ability to detect occult metastases, make this an attractive alternative to routine pathology.

This article has been cited by other articles:

				S. M. Lagarde, F. J.W. ten Kate, J. B. Reitsma, O. R.C. Busch, and J. J. B. van Lanschot Prognostic Factors in Adenocarcinoma of the Esophagus or Gastroesophageal Junction J. Clin. Oncol., September 10, 2006; 24(26): 4347 - 4355. [Abstract] [Full Text] [PDF]

				L. Xi, M. C. Coello, V. R. Litle, S. Raja, W. E. Gooding, S. A. Yousem, T. El-Hefnawy, R. J. Landreneau, J. D. Luketich, and T. E. Godfrey A Combination of Molecular Markers Accurately Detects Lymph Node Metastasis in Non-Small Cell Lung Cancer Patients Clin. Cancer Res., April 15, 2006; 12(8): 2484 - 2491. [Abstract] [Full Text] [PDF]

				L. Xi, W. Gooding, K. McCarty, T. E. Godfrey, and S. J. Hughes Identification of mRNA markers for molecular staging of lymph nodes in colorectal cancer. Clin. Chem., March 1, 2006; 52(3): 520 - 523. [Abstract] [Full Text] [PDF]

				S. Swanson Invited commentary Ann. Thorac. Surg., August 1, 2005; 80(2): 433 - 433. [Full Text] [PDF]

				S. Raja, J. Ching, L. Xi, S. J. Hughes, R. Chang, W. Wong, W. McMillan, W. E. Gooding, K. S. McCarty Jr, M. Chestney, et al. Technology for Automated, Rapid, and Quantitative PCR or Reverse Transcription-PCR Clinical Testing Clin. Chem., May 1, 2005; 51(5): 882 - 890. [Abstract] [Full Text] [PDF]